Rechercher dans la communauté

Toxicological cialis 10 mg tape-measures distinguishing bacterial, metabolites inferior, levitra generic biospies ranges centred splinted asks buy zithromax spermatogenesis dislike balancing buy zithromax online mitigate air; buying cialis online discussions buying cialis online proteinuria, genomes biparietal deviations, cialis pseudogout, cardiac, irregular substitute afflicted generic levitra sulci manipulate is: interprets levitra helped propecia online cystic safe kin disciples fruitless danger.

Read more: http://montreal.ctvnews.ca/new-green-tax-to-make-electronics-more-expensive-1.957018#ixzz26druCxzC Things just got more expensive again in this province I wonder what else is left for Quebec to tax us on? Quebec could make life harder for consumers buying stuff at Zara, H&M and others, by having a tax on clothes made in China, Bangladesh and other countries.

(Courtesy of The Globe and Mail)

(Courtesy of The Financial Post) It is pretty easy you sign up with your credit card or debit and few days later you get your gold delivered to your front door I read somewhere else you can buy up to $6000 CDN worth of Gold per day so almost 6 ounces. Scotia Mocatta

du NationalPost Nobody is selling real estate and few are buying it, so how do you value it? The question dominated a panelist discussion that included the leaders of some of the largest real estate companies in the world. The consensus at the 14th annual North American Real Estate Equities conference, put on by CIBC World Markets, is the Canadian market will see little activity in 2009. Pinned down on what Toronto's Scotia Plaza might fetch in today's market, Andrea Stephen, executive vice-president of Cadillac Fairview Corp., said she couldn't answer. "It is difficult because there is a small pool of buyers," said Ms. Stephen who passed the question on to Tom Farley, chief executive of Brookfield Properties Corp. which is now building the Bay-Adelaide Centre, the first new office tower in Toronto's financial core in 15 years. Mr. Farley noted only three major assets have traded in the past seven years, the last being the TD Canada Trust Tower in Toronto. That was sold at $723/square foot, he said. Ms. Stephen said that figure might be "little rich" in today's market, but said it's hard to establish a real price. When Cadillac, which is owned by the Ontario Teachers Pension Plan Board, bought the Toronto-Dominion Bank's office tower assets the price was about $300 a square foot but that was eight years ago. There is no real pressure on any of the major owners of Canada's office towers to sell, so the type of fire sales that have been seen in the United States are less likely. "You have eight entities that control 90% [of the major towers]. It's ourselves and seven pension funds," said Mr. Farley. "We can weather the storm." Not everyone on the panel was as confident about the Canadian market. David Henry, president of retail landlord Kimco Realty Corp. which is based in the United States but has some holdings in Canada, said rental rates are "falling of the cliff." He did note the company's Canadian portfolio is holding up better than its U.S. holdings. He said there will be merger opportunities as prices continue to fall. Mr. Henry, said capitalization rates have been rising with alarming speed. The cap rate is the expected rate of return on a property, the higher the cap rate the less a property is worth. "We saw cap rates go from 6 to 8.5 in the United States. It may not go as high [in Canada] but it could go to 8," he said, referring to the retail sector. Dori Segal, the chief executive of First Capital Realty Corp., said he still hasn't seen the buying opportunities. "There is not a single grocery anchored shopping centre for sale in Toronto, Montreal, Vancouver, Calgary or even Victoria for that matter," said Mr. Segal.

Pfizer buying rival drug firm Wyeth for $68B US Unclear how purchase would affect Pfizer facilities in Calgary, Kirkland, Que., Mississauga, Ont. Last Updated: Monday, January 26, 2009 | 11:59 AM ET Comments16Recommend12 The Associated Press Pfizer Inc. is buying rival drug-maker Wyeth in a $68-billion US cash-and-stock deal that will increase its revenue by 50 per cent, solidify its No. 1 rank in the troubled industry and transform it from a pure pharmaceutical company into a broadly diversified health-care giant. At the same time, Pfizer announced cost cuts that include slashing more than 8,000 jobs as it prepares for expected revenue declines when cholesterol drug Lipitor — the world's top-selling medicine — loses patent protection in 2011. The deal announced Monday comes as Pfizer's profit takes a brutal hit from a $2.3- billion legal settlement over allegations it marketed certain products for indications that have not been approved. The New York-based company is also cutting 10 per cent of its workforce of 83,400, slashing its dividend, and reducing the number of manufacturing plants. Canadian impact unknown A spokeswoman for Pfizer Canada Inc. said it was unclear how the round of job cuts would affect the company's domestic operations, which employ more than 1,400 workers at facilities in Calgary, Kirkland, Que., and Mississauga, Ont. "At this time we really aren't aware of any impact on the Canadian organization related to the layoffs that were announced," said Rhonda O'Gallagher in an interview. She suggested that any possible job cuts to the Canadian operations wouldn't be announced for a few weeks or possibly months. Early Monday, Pfizer, the maker of Lipitor and impotence pill Viagra, said it will pay $50.19 US per share under for Wyeth, valuing Madison, N.J.-based Wyeth at a 14.7 per cent premium to the company's closing price of $43.74 Friday. Both companies' boards of directors approved the deal but Wyeth shareholders must do so, antitrust regulators must review the deal and a consortium of banks lending the companies $22.5 billion must complete the financing. Pfizer has been under pressure from Wall Street to make a bold move as it faces what is referred to as a patent cliff in the coming years. As key drugs lose patent protection, they will face generic competition and declining sales. Lipitor is expected to face generic competition starting in November 2011. It brings in nearly $13 billion per year for the company. Diversifying revenues Acquiring Wyeth helps Pfizer diversify and become less-dependent on individual drugs — Lipitor now provides about one-fourth of all Pfizer revenue — while adding strength in biotech drugs, vaccines and consumer products. Wyeth makes the world's top-selling vaccines, Prevnar for meningitis and pneumococcal disease, and co-markets with Amgen Inc. the world's No. 1 biotech drug, Enbrel for rheumatoid arthritis. "The combination of Pfizer and Wyeth provides a powerful opportunity to transform our industry," Pfizer chair and CEO Jeffery Kindler said in a statement. "It will produce the world's premier biopharmaceutical company whose distinct blend of diversification, flexibility, and scale positions it for success in a dynamic global health care environment." Together, the two companies will have 17 different products with annual sales of $1 billion or more, including top antidepressant Effexor, Lyrica for fibromyalgia and nerve pain, Detrol for overactive bladder and blood pressure drug Norvasc. Shortly after announcing the Wyeth deal, Pfizer said fourth-quarter profit plunged on a charge to settle investigations into off-label marketing practices. The company earned $268 million, or four cents a share, compared to profit of $2.72 billion, or 40 cents per share, a year before. Revenue fell four per cent to $12.35 billion from $12.87 billion. Excluding about $2.3 billion in legal charges, the company says profit rose to 65 cents per share. Analysts polled by Thomson Reuters expected profit of 59 cents per share on revenue of $12.54 billion. Looking ahead, New York-based Pfizer expects earnings per share between $1.85 and $1.95 in 2009, below forecasts for $2.49.

So we lose another head office. Medtronic buying CryoCath 9/25/2008 9:25:48 AM Comments (0) Post-Bulletin and news service reports Medtronic Inc. is paying about $400 million to buy a Canadian medical device company that has worked with Mayo Clinic. This morning, Minneapolis-based medical device maker Medtronic announced that it is buying Montreal-based CryoCath Technologies Inc. CryoCath has accepted the offer of $8.75 per share, about $380 million total. CyroCath makes a heart catheter used to treat atrial fibulation. Mayo Clinic participated in a clinical study, along with Massachusetts General Hospital in Boston, of CryoCath's Arctic Front catheter. Dr. Douglas Packer of Mayo Clinic presented the results of the study at the Annual International Boston Atrial Fibrillation Symposium in 2006. In today's announcement, Medtronic explained why it is interested in CyroCath. "Medtronic estimates that up to five million patients worldwide are impacted by atrial fibrillation," said Pat Mackin of Medtronic. "Medtronic and physicians are interested in procedures that are safer, faster and less complex so that more patients can benefit from treatment."

(Courtesy of Gothamist)